open access

Vol 13, No 1 (2010)
Reviews
Published online: 2010-12-01
Submitted: 2012-01-23
Get Citation

Nuclear medicine in multiple myeloma — more than diagnosis

Giuseppe Lucio Cascini, Vincenzo Cuccurullo, Oscar Tamburrini, Luigi Mansi, Antonio Rotondo
Nucl. Med. Rev 2010;13(1):32-38.

open access

Vol 13, No 1 (2010)
Reviews
Published online: 2010-12-01
Submitted: 2012-01-23

Abstract

Multiple myeloma (MM) is a neoplastic monoclonal proliferation of plasma cells, mainly involving bone marrow. To properly stage and manage patients with MM the clinician needs, at first, a complete skeletal survey, being more rarely present also extra skeletal locations. Today none of the available diagnostic imaging methods is able alone to answer to all the questions regarding staging, treatment, and follow up. Continuing to be alive the role of traditional radiology, implemented information can be added by CT and MRI. Concerning nuclear medicine, bone scintigraphy is affected by its low sensitivity. Tc-99m MIBI has been proposed in staging and in follow up, with most relevant clinical information deriving from the correlation of its whole body uptake’s distribution with extent and activity of the disease. The prognostic value of MIBI has also been demonstrated. PET-FDG has been proposed in MM for its ability to detect whole-body metabolic active disease, giving relevant information in staging and prognosis. First studies have demonstrated that PET-FDG is more sensitive than other imaging modalities for localizing extra medullary sites of disease.

Nuclear Med Rev 2010; 13, 1: 32–38

Abstract

Multiple myeloma (MM) is a neoplastic monoclonal proliferation of plasma cells, mainly involving bone marrow. To properly stage and manage patients with MM the clinician needs, at first, a complete skeletal survey, being more rarely present also extra skeletal locations. Today none of the available diagnostic imaging methods is able alone to answer to all the questions regarding staging, treatment, and follow up. Continuing to be alive the role of traditional radiology, implemented information can be added by CT and MRI. Concerning nuclear medicine, bone scintigraphy is affected by its low sensitivity. Tc-99m MIBI has been proposed in staging and in follow up, with most relevant clinical information deriving from the correlation of its whole body uptake’s distribution with extent and activity of the disease. The prognostic value of MIBI has also been demonstrated. PET-FDG has been proposed in MM for its ability to detect whole-body metabolic active disease, giving relevant information in staging and prognosis. First studies have demonstrated that PET-FDG is more sensitive than other imaging modalities for localizing extra medullary sites of disease.

Nuclear Med Rev 2010; 13, 1: 32–38

Get Citation

Keywords

myeloma; diagnostic imaging; nuclear medicine; Tc-99m MIBI; PET-FDG

About this article
Title

Nuclear medicine in multiple myeloma — more than diagnosis

Journal

Nuclear Medicine Review

Issue

Vol 13, No 1 (2010)

Pages

32-38

Published online

2010-12-01

Bibliographic record

Nucl. Med. Rev 2010;13(1):32-38.

Keywords

myeloma
diagnostic imaging
nuclear medicine
Tc-99m MIBI
PET-FDG

Authors

Giuseppe Lucio Cascini
Vincenzo Cuccurullo
Oscar Tamburrini
Luigi Mansi
Antonio Rotondo

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl